Japan stock market week to Nov 10, 2008

17 November 2008

Tokyo posted a modest advance in the week ended November 10. The Nikkei 225 was up 5.9%, recovering the psychologically-important 9,000 level at the close, while the Topix index rose 5.7%. The market recorded solid daily gains early in the week in anticipation of an overwhelming victory for Democrat Barack Obama in the US presidential election, generating an expectation for increases in economy-stimulating measures. However, it lost strength steeply mid-week, although a daily gain was recorded in the last trading day, because investors refocused on the gloomy outlook for the US, Japanese and global economies. A surprisingly bearish earnings forecast for the current fiscal year unveiled by leading export-oriented blue chip company Toyota discouraged investors. The pharmaceutical index was up 4.9%, underperforming the market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight